NEW YORK – Veracyte's planned acquisition of precision oncology firm Decipher Biosciences for $600 million in cash and stock, announced on Wednesday, should help the firm expand its global reach into the cancer diagnostic space using its nCounter platform.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.